Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs Cleerly ISCHEMIA

Acumen HPI is integrated directly into existing Edwards Lifesciences HemoSphere/EV1000 bedside monitoring platforms, providing continuous, real-time predictive insights and alerts during critical care or surgery. This direct integration into the immediate clinical workflow for dynamic physiological monitoring offers a more seamless and immediate user experience. While Cleerly ISCHEMIA offers interactive web-based reports and API integration, its workflow involves data transfer and subsequent review, making it less 'real-time' for acute decision-making.

Both tools offer significant clinical value, but Acumen HPI provides immediate, predictive insights for acute, life-threatening hypotensive events, with studies demonstrating a significant reduction in the duration and incidence of intraoperative hypotension. This proactive intervention capability directly impacts patient safety during critical procedures. Cleerly ISCHEMIA offers robust diagnostic and prognostic value for chronic heart disease management, leading to improved diagnostic accuracy and reduced unnecessary testing, but its impact is less immediate in an acute setting.

Cleerly ISCHEMIA offers more transparency regarding its pricing structure, with estimated costs for the analysis and clear information on CPT codes and growing insurance coverage, allowing for more predictable financial planning. Acumen HPI requires direct contact for pricing, and while some hardware costs are known, the software pricing remains opaque. The clear billing pathway for Cleerly ISCHEMIA enhances its perceived value for healthcare providers.

Both tools are FDA cleared and HIPAA compliant, indicating strong foundational readiness. However, Cleerly ISCHEMIA explicitly mentions a Business Associate Agreement (BAA), web-based deployment with secure data transfer options (VPN/virtual appliance), and API integration with PowerScribe [JSON]. These features demonstrate a comprehensive approach to enterprise-level data governance, security, and integration within diverse healthcare IT environments, giving it a slight edge.

Both tools are highly innovative. Acumen HPI's real-time predictive analytics for an imminent physiological event is groundbreaking for acute care. However, Cleerly ISCHEMIA's ability to derive detailed functional and morphological insights, including non-invasive FFR estimation and comprehensive plaque characterization, from anatomical CCTA scans represents a significant paradigm shift in non-invasive cardiac diagnostics. Cleerly has also received multiple industry awards for its innovative use of AI, including 'Best Overall AI Solution'.

Acumen HPI benefits from being part of Edwards Lifesciences (now BD Critical Care), a large, established medical device company with a robust support infrastructure, including explicit mention of '24/7 Technical support' and 'Edwards clinical education,' along with specific setup guides. While Cleerly provides various resources like publications and webinars, explicit details on technical support availability are not as prominently featured, suggesting a less comprehensive and readily available support system compared to a major medical device manufacturer.